Colchicine could thus constitute a new and important treatment for secondary prevention after stroke, by targeting inflammation via pleiotropic actions, including the inhibition of interleukin-1β (IL1-β) and IL-6 synthesis, and the reduction of microtubule-dependent leucocyte motility and mitosis [15]. The gene discussed is IL1B; the disease is stroke disorder.